SOPHiA GENETICS SA

Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL). It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions.

In 2014, the company introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine), which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples. The platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research.

In 2018, the company set up its first research and development center in France and made acquisition of a France -based molecular biology and genetic analytics software development company, Interactive Biosoftware. That same year, Sophia Genetics opened its U.S. headquarters in Boston, Massachusetts.

Prior to its initial public offering, Sophia Genetics raised approximately $250 million across several private funding rounds. The company closed a $13.75 million Series B round in 2014, led by Invoke Capital, Swisscom, and Endeavour Vision. This was followed by a $15 million Series C round in 2015, led by Belgian entrepreneur Marc Coucke. In September 2017, the company raised $30 million in a Series D round led by Balderton Capital. A $77 million Series E round followed in January 2019, led by Generation Investment Management. The company's largest private round, a $110 million Series F, closed in October 2020, led by aMoon and Hitachi Ventures, bringing its total funding raised since founding to approximately $250 million.

In August 2020, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus. Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio.

In July 2021, Sophia Genetics went public with an IPO backed by J.P. Morgan, Morgan Stanley, and Credit Suisse.